In support of a protective potential of PGC-1α in EAE/MS, treatment of mice with resveratrol, a widely used inducer of its expression through the activation of Sirtuin 1 (SIRT1) [99], has been linked to clinical improvements in relapsing-remitting acute [130] as well as in chronic EAEs [131,132,133]. This evidence concerns the gene SIRT1 and myeloid sarcoma.